Navigation Links
Materia Licenses Metathesis Catalyst Platform to Eisai

PASADENA, Calif.--(BUSINESS WIRE)--Jun 20, 2007 - Materia, Inc., a catalyst technology company, announced today the licensing of its metathesis platform to Eisai Co., Ltd., a leading Japanese pharmaceutical company, for use in drug discovery and development. The non-exclusive license agreement provides rights to discover, develop, and patent pharmaceutical compounds and related processes using the Company's catalysts and associated intellectual property.

Metathesis catalysts enable the formation and manipulation of carbon-carbon bonds in the synthesis of entirely new pharmaceutical products with superior properties as well as in the development of new, more efficient and low cost production processes for existing products. Materia's catalysts include those from Professor Robert Grubbs at Caltech who won the Nobel Prize for the technology in 2005.

"We are pleased that Eisai accepts the value of Materia's technology in drug discovery and process chemistry and look forward to its exciting progress," stated Dr. Michael Giardello, Materia's Chief Executive Officer. "We believe that this agreement further validates metathesis' broad potential for the pharmaceutical industry and Materia's unique intellectual property and position as the partner of choice."

About Materia

Materia was founded in 1998 to commercialize olefin metathesis catalyst technology. This market-enabling, Nobel Prize winning, green chemical technology enables chemical compounds to be synthesized with greater efficiency, under less stringent reaction conditions, and with reduced byproducts and hazardous waste. As stated by the Royal Swedish Academy of Sciences when awarding the 2005 Nobel Prize, "metathesis is an example of how important basic science has been applied for the benefit of man, society, and the environment." For more information, visit: www.materia-inc.com.

Contact

Materia, Inc.
John Kibler, 626- 584-8400


'"/>




Related medicine technology :

1. Catalyst Pharmaceutical Partners, Inc. Announces Top-Line Results of Its Bioequivalence Study of CPP-109 (Vigabatrin), the Companys Investigational Drug to Treat Cocaine and Methamphetamine Addiction
2. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
3. Pieris Progresses Development of its Proprietary Biotherapeutics Platform: Successful Demonstration of Dual Targeting With Duocalin(R) Technology
4. Indivumed Study Provides Sound Scientific Basis for a Predictive Drug Test- Platform
5. Abraxis BioScience Presents Pre-Clinical Findings That Support Role of SPARC Expression in Cancer and the Role of the Nanoparticle Albumin Bound (nab) Technology Platform in Targeting the Pathway
6. AVEO Pharmaceuticals Novel Oncology Research Platform and Clinical Pipeline to Be Featured at AACR
7. Clinical Data on Eisais Oncology Pipeline to be Presented at ASCO Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/2/2020)... ... 02, 2020 , ... On April 15, the Center for ... annual Medical Hero Appreci-a-thon to bring the global clinical research community together to ... and study volunteers. CISCRP invites the public to participate in this free ...
(Date:4/1/2020)... ... April 01, 2020 , ... ... continuing her partnership with the esteemed Haute Beauty network. , The Haute Beauty ... Dr. Green as a leading Anti-Aging Expert. , Haute Beauty offers a prominent ...
(Date:4/1/2020)... OAKLAND, Calif. (PRWEB) , ... April 01, 2020 ... ... Live” allows subscribers to sign up today, with the first live-streaming broadcast ... (PST) every weekday and feature a host interviewing a variety of animal keepers ...
Breaking Medicine Technology:
(Date:4/1/2020)... ... April 02, 2020 , ... AAGL Gynecologic ... pm ET- to discuss surgical safety practices in response to the COVID-19 crisis. ... University Healthcare Network in New Orleans and Amsterdam University Medical Center in the ...
(Date:4/1/2020)... ... April 01, 2020 , ... Global mobile data platform provider Zerion ... adjusting to new needs based on COVID-19. , As cases continue to rise across ... types. , Zerion will extend support by offering free basic iFormBuilder accounts and forms ...
(Date:3/28/2020)... ROCKVILLE, Md. (PRWEB) , ... March 27, 2020 ... ... a new way of life as COVID-19 cases grow by the day, people ... for children with language disorders—who have difficulties with social interactions in the best ...
(Date:3/28/2020)... ... March 28, 2020 , ... Confluent Health is proud ... therapist-owned rehabilitation company since 1985 specializing in the treatment of orthopedic, sports, and ... more than 30 years ago, we have been committed to providing excellent quality ...
(Date:3/22/2020)... ... March 21, 2020 , ... The ... Modular Home Builders Association (MHBA), have been working with state and federal officials ... been advocating for greater use of modular construction to address the nation’s affordable ...
Breaking Medicine News(10 mins):